{"id":"augmentin-es-600","safety":{"commonSideEffects":[{"rate":"15-30%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Nausea"},{"rate":"3-5%","effect":"Vomiting"},{"rate":"3-5%","effect":"Rash"},{"rate":"3-5%","effect":"Abdominal pain"},{"rate":"1-3%","effect":"Allergic reaction"}]},"_chembl":{"chemblId":"CHEMBL3909450","moleculeType":"Small molecule","molecularWeight":"443.59"},"_dailymed":{"setId":"59979859-8c9b-4173-a5e3-2e6312fd9d79","title":"AUGMENTIN ES-600 (AMOXICILLIN AND CLAVULANATE POTASSIUM) FOR SUSPENSION [USANTIBIOTICS, LLC\n]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Augmentin ES-600 contains amoxicillin and clavulanic acid. Amoxicillin is a beta-lactam antibiotic that disrupts bacterial cell wall formation by inhibiting penicillin-binding proteins. Clavulanic acid is a beta-lactamase inhibitor that protects amoxicillin from degradation by bacterial beta-lactamases, extending the spectrum of activity to include beta-lactamase-producing strains that would otherwise be resistant to amoxicillin alone.","oneSentence":"Augmentin ES-600 is a combination antibiotic that inhibits bacterial cell wall synthesis by blocking penicillin-binding proteins, with enhanced coverage against beta-lactamase-producing organisms.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:19:44.520Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute otitis media in pediatric patients"},{"name":"Sinusitis"},{"name":"Community-acquired pneumonia"},{"name":"Urinary tract infections"},{"name":"Skin and soft tissue infections"}]},"trialDetails":[{"nctId":"NCT05340257","phase":"PHASE2","title":"A Pharmacokinetics and Safety Study of Augmentin ES-600 in Children With CAP and ABRS","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2023-10-14","conditions":"Infections, Bacterial","enrollment":""},{"nctId":"NCT04600752","phase":"PHASE4","title":"Study to Evaluate the Safety and Clinical Efficacy of Augmentin® Extra Strength-600 in Children With Acute Otitis Media in India","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-05-07","conditions":"Otitis Media, Infections, Respiratory Tract, Respiratory Tract Infections","enrollment":310},{"nctId":"NCT00778414","phase":"NA","title":"Bioequivalence Study of Amoxicillin-Clavulanic Acid 600 mg - 42.9 mg/ 5 mL Oral Suspension Under Fasting Conditions","status":"COMPLETED","sponsor":"Ranbaxy Laboratories Limited","startDate":"2006-06","conditions":"Healthy","enrollment":48}],"_emaApprovals":[],"_faersSignals":[{"count":27,"reaction":"DIARRHOEA"},{"count":22,"reaction":"VOMITING"},{"count":14,"reaction":"TOOTH DISCOLOURATION"},{"count":10,"reaction":"DRUG INEFFECTIVE"},{"count":9,"reaction":"PYREXIA"},{"count":9,"reaction":"URTICARIA"},{"count":8,"reaction":"PRURITUS"},{"count":8,"reaction":"RASH"},{"count":7,"reaction":"MEDICATION ERROR"},{"count":6,"reaction":"PHARMACEUTICAL PRODUCT COMPLAINT"}],"_approvalHistory":[{"date":"20021017","type":"SUPPL","sponsor":"US ANTIBIOTICS","applicationNumber":"NDA050755"},{"date":"20030512","type":"SUPPL","sponsor":"US ANTIBIOTICS","applicationNumber":"NDA050755"},{"date":"20021127","type":"SUPPL","sponsor":"US ANTIBIOTICS","applicationNumber":"NDA050755"},{"date":"20110826","type":"SUPPL","sponsor":"US ANTIBIOTICS","applicationNumber":"NDA050755"},{"date":"20220630","type":"SUPPL","sponsor":"US ANTIBIOTICS","applicationNumber":"NDA050755"},{"date":"20110826","type":"SUPPL","sponsor":"US ANTIBIOTICS","applicationNumber":"NDA050755"},{"date":"20150316","type":"SUPPL","sponsor":"US ANTIBIOTICS","applicationNumber":"NDA050755"},{"date":"20090116","type":"SUPPL","sponsor":"US ANTIBIOTICS","applicationNumber":"NDA050755"},{"date":"20010622","type":"ORIG","sponsor":"US ANTIBIOTICS","applicationNumber":"NDA050755"},{"date":"20140408","type":"SUPPL","sponsor":"US ANTIBIOTICS","applicationNumber":"NDA050755"},{"date":"20041217","type":"SUPPL","sponsor":"US ANTIBIOTICS","applicationNumber":"NDA050755"},{"date":"20040603","type":"SUPPL","sponsor":"US ANTIBIOTICS","applicationNumber":"NDA050755"},{"date":"20240501","type":"SUPPL","sponsor":"US ANTIBIOTICS","applicationNumber":"NDA050755"},{"date":"20021204","type":"SUPPL","sponsor":"US ANTIBIOTICS","applicationNumber":"NDA050755"},{"date":"20220922","type":"SUPPL","sponsor":"US ANTIBIOTICS","applicationNumber":"NDA050755"},{"date":"20241220","type":"SUPPL","sponsor":"US ANTIBIOTICS","applicationNumber":"NDA050755"},{"date":"20080417","type":"SUPPL","sponsor":"US ANTIBIOTICS","applicationNumber":"NDA050755"},{"date":"20140930","type":"SUPPL","sponsor":"US ANTIBIOTICS","applicationNumber":"NDA050755"},{"date":"20041110","type":"SUPPL","sponsor":"US ANTIBIOTICS","applicationNumber":"NDA050755"}],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Augmentin (ES)-600","genericName":"Augmentin (ES)-600","companyName":"GlaxoSmithKline","companyId":"glaxosmithkline","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Augmentin ES-600 is a combination antibiotic that inhibits bacterial cell wall synthesis by blocking penicillin-binding proteins, with enhanced coverage against beta-lactamase-producing organisms. Used for Acute otitis media in pediatric patients, Sinusitis, Community-acquired pneumonia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}